Ground Truth

The honest read · evidence-graded · sells nothing

The honest read on every peptide.

What the science actually says, what real people report, and whether it's even worth it, across 42 compounds. We've been burned by this ourselves, so we did the homework, weighed the real-world record, and graded all of it. None of it's for sale.

Every source is public and clickable, so you can check our work yourself. No login, no annual fee, no paywall to find out whether you're being sold a story.

Then build your own protocol and see what it should cost.

Build your own protocol →

Free to build. Pick compounds, see the honest price range, print it, and budget it however you choose to source. No account.

Build your own protocol

Pick a goal. See what actually works and what a fair month should cost. Print your protocol. No account.

  • C

    BPC-157 / TB-500 Blend 10mg/10mg

    ~$75/vial

  • C

    BPC-157

    ~$42/vial

  • C

    BPC-157 / TB-500 Blend 5mg/5mg

    ~$44/vial

Tap + Add to start your protocol and see the month build.

Already know your dose?

Skip the planning and get the exact syringe units for a single vial. Or open the full reconstitution tool →

Reconstitution calculator

How many units do I draw?

Pick your peptide and vial size, then set how much water you add and how much you want to take, type a number or tap −/+. We do the insulin-syringe math.

Vial amountmg in vial
Water you addmL
Dose you takemcg

For 250 mcg, draw

10 units

on a U-100 insulin syringe (0.10 mL)


Concentration

2500 mcg/mL

Each unit

25.0 mcg

U-100 syringe: 100 units = 1 mL. Presets are typical reported starting points, not recommended doses. Confirm your actual vial size before you draw.

If you remember nothing else

The key things to keep in mind.

01

Take control of your own health.

Nobody is coming to optimize you. The whole point is to make your own calls with your eyes open, not to hand them to a vendor.

02

The science is mostly thin.

For most of these, the honest answer is we don't really know yet. That's not a knock, it's just the state of the evidence.

03

Measure, don't guess.

Bloodwork, body composition, and a certificate of analysis on every vial. The people who get burned are the ones guessing.

04

Follow the money.

Before you believe a claim, ask who profits from you believing it. We flag the conflict on every expert and seller we cite.

05

It might be placebo. So what?

If you genuinely feel better, that's real to you. Just know that might be what you're paying peptide prices for, and price it accordingly.

06

Go slow. One thing at a time.

Change one variable, then measure. Stacking four compounds at once is exactly how people end up with no idea what did what.

Why is the science so thin? Follow the money →

What we actually ran, and why → Real protocols, told as decisions, next to the graded science and never instead of it.

The watch desk

What just happened, and what's next.

Oct 12, 2026Eleven weeks after the peptide vote, FDA still has no rule and no date for the next panelWe rechecked on October 12, 2026. A Federal Register search of FDA documents through October 8 shows no proposed rule adding BPC-157, KPV, TB-500, MOTS-c, Semax or Epitalon to the 503A Bulks List. FDA's meeting page for the second tranche (LL-37, GHK-Cu, Dihexa acetate, Melanotan II and PEG-MGF) still says only 'before the end of February 2027', with no date, notice or docket. The public docket for the July meeting (FDA-2025-N-6895) closed on July 22. One correction from this pass: FDA has posted no vote tallies, so every number is press-reported, and the Epitalon no count is reported as 4 or 5; we now say that instead of printing one figure. The 503B side is also still open: FDA's April 30 proposal to keep semaglutide, tirzepatide and liraglutide off the outsourcing-facility bulks list closed for comment on July 30, 2026 and we found no final decision. Nothing about what a pharmacy may lawfully compound has changed.regulatory · FDA, Pharmacy Compounding Advisory Committee meeting page ↗Oct 8, 2026New PubMed systematic review scrutinizes human BPC-157 evidence in orthopaedicsA PRISMA-compliant, PROSPERO-registered systematic review in Acta Orthopaedica Belgica searched Embase, PubMed, Cochrane and ClinicalTrials.gov through June 2026 to evaluate BPC-157's human efficacy and safety evidence for orthopaedic/regenerative use.trial · PubMed / Acta Orthop Belg ↗Verified automatically, source linkedOct 1, 2026FDA says retatrutide cannot be compounded under federal law and counts nearly 1,000 compounded semaglutide reportsFDA's page on unapproved GLP-1 drugs, current as of October 1, 2026, states that retatrutide and cagrilintide cannot be used in compounding under federal law. It says FDA has warned telehealth companies, distributors and outsourcing facilities over retatrutide, and sellers who labeled semaglutide, tirzepatide, retatrutide, survodutide or mazdutide 'not for human consumption'. As of May 31, 2026 FDA had received 990 adverse-event reports for compounded semaglutide and more than 730 for compounded tirzepatide, which it says are likely underreported.regulatory · FDA, concerns with unapproved GLP-1 drugs ↗Sep 30, 2026Lilly's tirzepatide + eloralintide combo beats tirzepatide alone in Phase 2A mid-stage trial found Lilly's experimental tirzepatide/amylin-agonist combo produced greater weight loss than high-dose tirzepatide alone in obesity/T2D patients; Lilly plans Phase 3 trials by end of 2026, including a co-formulated single injection.trial · CNBC ↗Verified automatically, source linkedSep 29, 2026Retatrutide's TRIUMPH-1 and TRIUMPH-2 are now peer reviewed: 25.0% weight loss at 80 weeksTRIUMPH-1 (2,339 adults) appeared in the New England Journal of Medicine and TRIUMPH-2 (1,152 adults with type 2 diabetes) in The Lancet on September 29, 2026. In TRIUMPH-1 the 12 mg dose averaged 25.0% weight loss at 80 weeks against 3.9% on placebo counting everyone randomized; the 28.3% Lilly led with in May is the figure if everyone stayed on drug. Dysesthesia, an abnormal skin sensation, was more common on retatrutide than placebo in every phase 3 trial reported, and dropouts for side effects rose with dose. Lilly says it will file with FDA in the first quarter of 2027. Until approval, retatrutide is investigational and anything sold under its name is not Lilly's drug.trial · PubMed, TRIUMPH-1 (NEJM) ↗Sep 24, 2026Tirzepatide: SURMOUNT-1 3-year analysis shows most patients keep weight offA new 3-year analysis of SURMOUNT-1 found 70% of participants with prediabetes who hit their lowest weight on tirzepatide had regained less than 5% of baseline weight by year three, with glycemic benefits largely intact.trial · Medscape ↗Verified automatically, source linkedSep 18, 2026FDA warns Empower Pharmacy that adding a vitamin to compounded GLP-1s does not make them a different drugFDA's warning letter to Empower Clinic Services (Empower Pharmacy) found its tirzepatide-plus-niacinamide and semaglutide-plus-B12 products were essentially copies of the approved drugs under section 503A, and said the volume it was producing made the claimed differences look pretextual. This matters because 'it has B12 in it' has been one of the main ways compounded GLP-1s stayed on the market after the shortages ended. It is a letter, not a court ruling, but it tells you where FDA thinks the line is.regulatory · FDA, warning letter 738238 ↗Sep 10, 2026WADA approves its 2027 Prohibited List: a broader peptide warning, and GLP-1 drugs stay offWADA's Executive Committee approved the 2027 List on September 10, 2026, effective January 1, 2027. The peptide change is a caution, not a new named ban: WADA says named peptides are examples only and that an unnamed peptide may still be prohibited. Semaglutide and tirzepatide stay unlisted pending a second study of athletes. For context, the 2026 List already names BPC-157 under S0 and TB-500 under S2. We did not reach WADA's own summary of changes, so this rests on national anti-doping and Paralympic reports.regulatory · International Paralympic Committee ↗Sep 1, 2026FDA posts warning letters to five 'research use only' peptide sellersDated August 24, 2026 and posted September 1, the letters went to Peptide Partners, Peak Performance Peptides, Royal Peptides, NuScience Peptides and TXP Innovations (Tex Peptides). Products named in the Peptide Partners letter, the one we read in full, include semaglutide, tirzepatide, retatrutide, tesamorelin, SS-31 and PT-141, and other letters name tesamorelin-ipamorelin blends. FDA's reasoning is the part to remember: dosing information, injection instructions, dose calculators and bundled bacteriostatic water showed the products were meant for people, so the 'not for human use' label did not protect them. None of the six peptides from the July PCAC vote appears in the letter we read in full, but the logic applies to anyone selling any peptide this way.regulatory · FDA, warning letter to Peptide Partners LLC ↗Aug 12, 2026Lilly sues six sellers of 'research' retatrutide and refers more than 200 moreEli Lilly announced six lawsuits against U.S. businesses it says sell unapproved retatrutide: Aesthetic Envy Cosmetic Centers, Astra, Legendary Peptides, Striker Pharmacy, Texas Peptides and Lone Star Peptide. It also reported more than 200 individuals and entities to FDA, the Justice Department, state attorneys general and licensing boards. Retatrutide is still investigational, so anything sold under the name is not Lilly's drug. FDA's August 24 warning letters to five other sellers followed within two weeks.market · Healio ↗
See everything we track →

What this is

  • Everything we figured out, graded honestly on evidence and safety, with real labs as exhibit A.
  • The verification standard we wish we'd used before buying anything.
  • The free tools we actually use, with the honest layer on top.
  • Ground Control, the tool we built to track real experiments. And it's yours to copy.

What it isn't

  • Not a store. We're not selling you anything, ever.
  • Not a clinic, not an MLM, not a brand. Just people who got obsessed.
  • Not hype. If we can't back it up, we say so, with a citation.
  • Not anti-peptide. We're on them. We just won't call animal data human proof.

The method

Four questions. Never one number.

One rating hides the only thing that matters: proven for what?So every compound answers four plain questions instead. Does the science back it? Do real people feel it? Is it safe? And could it just be placebo? Two of them carry letter grades, and here's how those work.

Then we try to prove our own grade wrong before it ships, hunting for the disconfirming study, the failed trial, the conflict of interest. The grade you see is the one that survived.

Read our full method. Biases and all →
CricketsMixedBuzzLoudNothingAnimalEarlyHumanProvenDoes the science back it? →Do real people feel it? →BPC-157. Science C, real-world Moderate, safety C.TB-500. Science D, real-world Mixed, safety D.GHK-Cu. Science C, real-world Mixed, safety B.MOTS-c. Science D, real-world Faint, safety D.Tesamorelin. Science A, real-world Moderate, safety B.KPV (Lysine-Proline-Valine). Science D, real-world Faint, safety C.Pentadeca Arginate (PDA). Science D, real-world Mixed, safety D.ARA-290 (Cibinetide). Science B, real-world Faint, safety B.LL-37 (cathelicidin). Science C, real-world Faint, safety E.Thymosin Alpha-1. Science A, real-world Moderate, safety B.VIP (Vasoactive Intestinal Peptide). Science B, real-world Mixed, safety C.Cartalax (AED, Ala-Glu-Asp cartilage peptide bioregulator). Science D, real-world Faint, safety D.Ipamorelin. Science B, real-world Moderate, safety C.CJC-1295 (no-DAC / Modified GRF 1-29). Science D, real-world Moderate, safety C.Sermorelin. Science B, real-world Moderate, safety B.Epitalon (Epithalon). Science B, real-world Faint, safety C.Semax (N-Acetyl Semax). Science C, real-world Moderate, safety C.Selank (N-Acetyl Selank). Science B, real-world Moderate, safety B.PT-141 (Bremelanotide). Science A, real-world Moderate, safety C.DSIP (Delta Sleep-Inducing Peptide). Science B, real-world Mixed, safety C.Melanotan II. Science C, real-world Strong, safety E.AOD-9604. Science B, real-world Faint, safety B.5-Amino-1MQ. Science D, real-world Mixed, safety D.NAD+ (injectable). Science B, real-world Moderate, safety C.Cagrilintide. Science A, real-world Moderate, safety B.Semaglutide. Science A, real-world Strong, safety C.Tirzepatide. Science A, real-world Strong, safety B.Retatrutide. Science A, real-world Strong, safety C.Survodutide. Science A, real-world Faint, safety B.Melanotan I (afamelanotide). Science A, real-world Mixed, safety B.SNAP-8 (Acetyl Octapeptide-3). Science D, real-world Mixed, safety B.AHK-Cu (Copper Tripeptide-3). Science E, real-world Faint, safety B.Cerebrolysin. Science B, real-world Moderate, safety C.Dihexa. Science E, real-world Faint, safety E.GHRP-2. Science C, real-world Moderate, safety C.GHRP-6. Science C, real-world Moderate, safety C.Hexarelin. Science C, real-world Mixed, safety D.Kisspeptin. Science B, real-world Mixed, safety C.MK-677 (Ibutamoren). Science B, real-world Strong, safety E.Pinealon. Science D, real-world Faint, safety C.SS-31 (Elamipretide). Science A, real-world Mixed, safety B.Thymulin. Science D, real-world Faint, safety C.

Every compound we cover, mapped: science across the bottom, real-world buzz up the side, dot color is safety. Almost all of it sits in the low-science corner. Click a dot for its profile.

What I'd actually bet on

Top 10, most effective.

Ranked by how much real effect I'd bet on: science first, real-world signal next, knocked down for placebo. The proven stuff wins. Most peptides don't.

  1. 01SemaglutideA
  2. 02TirzepatideA
  3. 03RetatrutideA
  4. 04TesamorelinA
  5. 05Thymosin Alpha-1A
  6. 06CagrilintideA
  7. 07Melanotan I (afamelanotide)A
  8. 08MK-677 (Ibutamoren)B
  9. 09PT-141 (Bremelanotide)A
  10. 10SurvodutideA

Evidence

The highest level of human evidence reached. Strong animal data does not move it.

AProven in humans

Multiple human randomized controlled trials, or FDA-approved.

BHuman-trial signal

At least one human randomized controlled trial.

CEarly human data

Human pilot or observational studies only, no RCT.

DAnimal only

Promising in animals; no meaningful human evidence.

ETheoretical

In vitro, mechanistic, or anecdote. No controlled data.

Safety

A composite roll-up. Not an absence of bad news.

AWell-tolerated

Extensive human safety data; benign, well-mapped profile.

BCharacterized

Well-studied; real but manageable risks under monitoring.

CThinly characterized

No red flags observed, but human exposure is small.

DUncharacterized

Little or no human safety data exists either way.

EFlagged

Documented serious risks or major theoretical red flags.

FHarmful

Known to cause serious harm.

What rolls up into a safety grade

Volume of human safety dataSeverity of known adverse eventsTheoretical mechanistic riskAvailability of long-term dataFDA safety communications and label warningsWidth of the therapeutic window

Reading the two together

A / BProven in people, with risks monitoredTirzepatide, Tesamorelin, Thymosin Alpha-1
C / CPromising in small human pilotsBPC-157, Semax, GHRP-2
D / DStriking in animals, unproven in peopleMOTS-c, TB-500, Pentadeca Arginate
E / ENo meaningful human data either wayDihexa

Why there's nothing to buy

We're not selling you anything.

This is just us showing you what we found. It will never sell you a peptide. If we ever do anything commercial, it lives somewhere else, walled off from this. The whole point is that we've got nothing to sell you, so we've got no reason to shade the truth.

A gradedcitedindependent

Bring it back to your own body

Track it on yourself.

The Truth Tracker is a free, private place to keep your bloodwork and DEXA results and chart every marker over time, so the data, not the vibes, tells you whether a compound actually did anything. Ask Ground Truth can even read your answers against your own numbers.

Open the Truth Tracker →

Rather self-host? The open-source Ground Control is yours to copy.

New posts

Want to know when we publish the next post? Drop your email. We post when we have something worth writing down, not on a schedule. No spam, nothing for sale, unsubscribe whenever.